DK1545710T3 - Anvendelse af N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]-phenyl)-pyridin-3-sulfonamid til behandling af cancer - Google Patents

Anvendelse af N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]-phenyl)-pyridin-3-sulfonamid til behandling af cancer

Info

Publication number
DK1545710T3
DK1545710T3 DK03792501T DK03792501T DK1545710T3 DK 1545710 T3 DK1545710 T3 DK 1545710T3 DK 03792501 T DK03792501 T DK 03792501T DK 03792501 T DK03792501 T DK 03792501T DK 1545710 T3 DK1545710 T3 DK 1545710T3
Authority
DK
Denmark
Prior art keywords
methylpyrazin
oxadiazol
sulfonamide
pyridine
methoxy
Prior art date
Application number
DK03792501T
Other languages
Danish (da)
English (en)
Inventor
David William Tonge
Sian Tomiko Taylor
Francis Thomas Boyle
Andrew Mark Hughes
Donna Johnstone
Marianne Bernice Ashford
Nigel Charles Barrass
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9942847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1545710(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1545710T3 publication Critical patent/DK1545710T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK03792501T 2002-08-23 2003-08-20 Anvendelse af N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]-phenyl)-pyridin-3-sulfonamid til behandling af cancer DK1545710T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0219660.8A GB0219660D0 (en) 2002-08-23 2002-08-23 Therapeutic use
PCT/GB2003/003653 WO2004018044A2 (fr) 2002-08-23 2003-08-20 Usage therapeutique

Publications (1)

Publication Number Publication Date
DK1545710T3 true DK1545710T3 (da) 2009-06-29

Family

ID=9942847

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03792501T DK1545710T3 (da) 2002-08-23 2003-08-20 Anvendelse af N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]-phenyl)-pyridin-3-sulfonamid til behandling af cancer

Country Status (32)

Country Link
US (2) US7820679B2 (fr)
EP (2) EP2072082A3 (fr)
JP (2) JP3663202B2 (fr)
KR (1) KR20050035280A (fr)
CN (1) CN100467023C (fr)
AR (1) AR041037A1 (fr)
AT (1) ATE427773T1 (fr)
AU (1) AU2003255835B8 (fr)
BR (1) BR0313655A (fr)
CA (1) CA2496476C (fr)
CL (1) CL2003001692A1 (fr)
CY (1) CY1110712T1 (fr)
DE (1) DE60327084D1 (fr)
DK (1) DK1545710T3 (fr)
ES (1) ES2323309T3 (fr)
GB (1) GB0219660D0 (fr)
HK (1) HK1077534A1 (fr)
IL (1) IL166730A0 (fr)
IS (1) IS2704B (fr)
MX (1) MXPA05001862A (fr)
MY (2) MY137595A (fr)
NO (1) NO330756B1 (fr)
NZ (1) NZ538114A (fr)
PL (1) PL375561A1 (fr)
PT (1) PT1545710E (fr)
RU (1) RU2340343C2 (fr)
SA (1) SA03240363B1 (fr)
SI (1) SI1545710T1 (fr)
TW (1) TWI302912B (fr)
UA (1) UA82071C2 (fr)
WO (1) WO2004018044A2 (fr)
ZA (1) ZA200501267B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
GB0514743D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Salt
WO2007111350A1 (fr) * 2006-03-28 2007-10-04 Osaka Bioscience Institute agent inhibiteur d'angiogenese ou d'invasion cancereuse de cellules de type mesenchymal ou amiboide
US20090062246A1 (en) * 2007-08-17 2009-03-05 Astrazeneca Ab Therapeutic treatment-014
MX2010003989A (es) * 2007-10-12 2010-04-27 Astrazeneca Ab Composicion zibotentan que contiene mannitol y/o celulosa microcristalina.
WO2009068906A2 (fr) * 2007-11-26 2009-06-04 Astrazeneca Ab Combinaisons comprenant zd4054 et un inhibiteur 172 des kinases de la famille src
WO2010004337A1 (fr) * 2008-07-10 2010-01-14 Astrazeneca Ab Combinaison comprenant du n-(3-méthoxy-5-méthylpyrazine-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phényle)pyridine-3-sulfonamide et du pemetrexed
CA2836474A1 (fr) * 2011-05-17 2012-11-22 Plexxikon Inc. Modulation de kinase et indications pour celle-ci
CN102491973A (zh) * 2011-12-15 2012-06-13 南京友杰医药科技有限公司 Zd-4054的合成方法
KR101855382B1 (ko) * 2015-12-31 2018-05-04 경북대학교 산학협력단 설폰아마이드계 화합물을 유효성분으로 포함하는 암의 예방, 치료 및 전이 억제용 약학적 조성물

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514691A (en) 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
TW270116B (fr) 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW224462B (fr) 1992-02-24 1994-06-01 Squibb & Sons Inc
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5965732A (en) 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
WO1996009818A1 (fr) 1994-09-27 1996-04-04 Merck & Co., Inc. Antagonistes du recepteur d'endotheline utilises dans le traitement des vomissements
GB2295616A (en) 1994-12-01 1996-06-05 Zeneca Ltd N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
GB9704762D0 (en) 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
WO1999048530A1 (fr) 1998-03-23 1999-09-30 Merck & Co., Inc. Therapie combinee pour le traitement de l'hyperplasie prostatique benigne
US6673832B1 (en) 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
PT1121111E (pt) 1998-10-15 2010-05-17 Imp Innovations Ltd Compostos para o tratamento de perda de peso
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
JP2003520785A (ja) 1999-12-15 2003-07-08 ブリストル−マイヤーズ スクイブ カンパニー アンジオテンシン・エンドセリン受容体二重拮抗薬としてのビフェニルスルホンアミド類
AR031679A1 (es) * 2000-02-16 2003-10-01 Astellas Pharma Inc Una composicion farmaceutica
EP1289558A2 (fr) 2000-05-31 2003-03-12 Warner-Lambert Company Llc Combinaisons d'un antagoniste de recepteur d'endotheline et compose anti-epileptique presentant des proprietes analgesiques ou de soulagement de la douleur
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
US20020055457A1 (en) 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
DE10113366A1 (de) 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Endothelinantagonisten
WO2002049630A2 (fr) * 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Methode pour prevenir et traiter une douleur par l'administration d'un antagoniste de l'endotheline
KR20040052489A (ko) 2001-03-06 2004-06-23 셀러지 파마세우티칼스, 인크 비뇨생식기 장애 치료용 화합물 및 그 방법
GB0108689D0 (en) 2001-04-05 2001-05-30 Medical Res Council Neuropathologies associated with expression of TNF-a
US20030092757A1 (en) 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
CN1514727A (zh) 2001-04-11 2004-07-21 ���Ͽع����޹�˾ 在前列腺癌患者中与健康相关的生活质量和与健康相关的质量-调节时间对疾病的进展的有利调节
WO2003006041A1 (fr) 2001-07-12 2003-01-23 Takeda Chemical Industries, Ltd. Agents prophylactiques/therapeutiques contre les tumeurs malignes
WO2003009805A2 (fr) 2001-07-23 2003-02-06 Brigham And Women's Hospital, Inc. Methodes analgesiques utilisant des ligands des recepteurs de l'endotheline
JP2003137814A (ja) 2001-08-10 2003-05-14 Takeda Chem Ind Ltd ＧｎＲＨアゴニストの併用剤
DE10155076A1 (de) 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
GB0223367D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
EP1761515B1 (fr) 2003-12-20 2008-11-05 MERCK PATENT GmbH Derives de tetrahydroquinoline 2-(hetero-)aryl substitues
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
GB0514743D0 (en) 2005-07-19 2005-08-24 Astrazeneca Ab Salt

Also Published As

Publication number Publication date
SI1545710T1 (sl) 2009-08-31
MY137595A (en) 2009-02-27
SA03240363B1 (ar) 2009-04-11
JP2005097312A (ja) 2005-04-14
TW200409768A (en) 2004-06-16
US7820679B2 (en) 2010-10-26
CL2003001692A1 (es) 2005-01-21
WO2004018044A8 (fr) 2004-06-24
TWI302912B (en) 2008-11-11
EP1545710B1 (fr) 2009-04-08
IL166730A0 (en) 2006-01-15
AU2003255835B8 (en) 2007-05-17
CN1688365A (zh) 2005-10-26
EP2072082A2 (fr) 2009-06-24
AR041037A1 (es) 2005-04-27
WO2004018044A2 (fr) 2004-03-04
ATE427773T1 (de) 2009-04-15
CA2496476C (fr) 2009-08-04
AU2003255835A1 (en) 2004-03-11
NO20050689L (no) 2005-03-21
CY1110712T1 (el) 2015-06-10
AU2003255835B2 (en) 2007-04-05
UA82071C2 (en) 2008-03-11
WO2004018044A3 (fr) 2004-05-06
IS2704B (is) 2010-12-15
EP2072082A3 (fr) 2009-12-23
KR20050035280A (ko) 2005-04-15
PT1545710E (pt) 2009-05-26
IS7766A (is) 2005-03-22
CA2496476A1 (fr) 2004-03-04
GB0219660D0 (en) 2002-10-02
MY136449A (en) 2008-10-31
BR0313655A (pt) 2005-06-21
CN100467023C (zh) 2009-03-11
HK1077534A1 (en) 2006-02-17
RU2340343C2 (ru) 2008-12-10
NO330756B1 (no) 2011-07-04
MXPA05001862A (es) 2005-06-03
NZ538114A (en) 2008-02-29
RU2005108349A (ru) 2005-08-27
JP2004083590A (ja) 2004-03-18
ZA200501267B (en) 2006-10-25
US20060094729A1 (en) 2006-05-04
US20110003831A1 (en) 2011-01-06
EP1545710A2 (fr) 2005-06-29
JP3663202B2 (ja) 2005-06-22
ES2323309T3 (es) 2009-07-13
PL375561A1 (en) 2005-11-28
DE60327084D1 (de) 2009-05-20

Similar Documents

Publication Publication Date Title
IS2704B (is) Notkun N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-[1,3,4-oxadíasól-2-ýl]fenýl)pýridín-3-súlfónamíðs við meðhöndlun á krabbameini
DK1620437T3 (da) 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
NL1025404A1 (nl) Pyrazolo-triazine verbindingen en gebruik daarvan.
DK1480615T3 (da) Superfin formoterolformulering
DK1562932T3 (da) 4 tetrazolyl-4-phenylpiperidinderivater til behandling af smerter
PT102750A (pt) Geladeira portatil aperfeicoada
DK1663236T3 (da) Kombination, der omfatter n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]-phenyl)-pyridin-3-sulfonamid og et bihosphanat
CY2013031I1 (el) Χρηση διϋδροϊμιδαζολονων για την αγωγη της επιληψιας στους σκυλους
DK1596870T4 (da) Højdosis-ibandronatformulering
IS7825A (is) Meðferðarfræðileg meðhöndlun
DE60234388D1 (de) Therapeutische lotion gegen dermatitis
NO20054053D0 (no) Triazolforbindelser anvendbare i terapi.
DK1487828T3 (da) Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme
ATE399523T1 (de) Haarbehandlungszusammensetzung
ZA200704104B (en) A combination of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic agent for the treatment of cancer
DK1496918T3 (da) Anvendelse af natriummetaarsenit til behandling af tumorer
ATE326208T1 (de) Haarbehandlungszusammensetzungen
DK1461042T3 (da) Anvendelse af desoxypeganin til behandling af klinisk depression
ATE515382T1 (de) Holzbehandlungsformulierung
IS8391A (is) Notkun á síramesíni við meðhöndlun á krabbameini
NO20040935L (no) Plaster for behandling av dysfunksjoner og forstyrrelser i negler.
ITMO20020368A1 (it) Mezzi di finitura perfezionati.
ES1051471Y (es) Sandalia multiforme perfeccionada
ES1051158Y (es) Monedero perfeccionado
ES1050962Y (es) Monedero perfeccionado.